Drug Trial Radar · NCT05879432
LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Mar 8, 2024
Primary completion
Mar 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Arch Biopartners Inc.Industry
- Sponsor type
- Industry
- First posted
- May 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR 2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR 3. Urine output \< 0.5 mL/kg/h for \>6 hours.
Conditions
- Acute Kidney Injury
- Cardiac Surgery
Interventions
LSALT PeptideDrug
LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
PlaceboDrug
0.9% saline solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteriaTime frame: 7 days
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary
Calgary, Alberta, Canada · Recruiting
Royal Columbian Hospital
New Westminster, British Columbia, Canada · Recruiting
Unity Health Toronto, St. Michael's Hospital
Toronto, Ontario, Canada · Recruiting
University Health Network, Toronto General Hospital
Toronto, Ontario, Canada · Recruiting
Gazi University
Yenimahalle, Ankara, Turkey (Türkiye) · Completed
Kosuyolu High Specialization Training and Research Hospital
Kartal, Istanbul, Turkey (Türkiye) · Completed
Erciyes University, Faculty of Medicine - Semiha Kibar Organ Transplant & Dialysis Hospital
Melikgazi, Kayseri, Turkey (Türkiye) · Completed
Kocaeli University, Faculty of Medicine Practices and Research Hospital
İzmit, Kocaeli, Turkey (Türkiye) · Completed
Sütçü İmam University, Faculty of Medicine
Kahramanmaraş, Onikişubat, Turkey (Türkiye) · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.